Trademark: 90611613
Status Date
Monday, January 22, 2024
Filing Date
Tuesday, March 30, 2021
Published for Opposition
Tuesday, December 7, 2021
5 Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, digital ulcers, and cerebrovascular diseases; vaccines; anxiolytics; anti-allergics; anti-infectives
The wording "LARZYLTA" has no meaning in a foreign language.
Jan 24, 2024
Notice Of Approval Of Extension Request E-Mailed
Jan 22, 2024
Sou Extension 4 Granted
Jan 22, 2024
Sou Extension 4 Filed
Jan 22, 2024
Sou Teas Extension Received
Jul 29, 2023
Notice Of Approval Of Extension Request E-Mailed
Jul 27, 2023
Sou Extension 3 Granted
Jul 27, 2023
Sou Extension 3 Filed
Jul 27, 2023
Sou Teas Extension Received
Jan 28, 2023
Notice Of Approval Of Extension Request E-Mailed
Jan 26, 2023
Sou Extension 2 Granted
Jan 26, 2023
Sou Extension 2 Filed
Jan 26, 2023
Sou Teas Extension Received
Aug 2, 2022
Notice Of Approval Of Extension Request E-Mailed
Jul 29, 2022
Sou Extension 1 Granted
Jul 29, 2022
Sou Extension 1 Filed
Jul 29, 2022
Sou Teas Extension Received
Feb 1, 2022
Noa E-Mailed - Sou Required From Applicant
Dec 7, 2021
Official Gazette Publication Confirmation E-Mailed
Dec 7, 2021
Published For Opposition
Nov 24, 2021
Teas Change Of Correspondence Received
Nov 24, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Nov 24, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Nov 17, 2021
Notification Of Notice Of Publication E-Mailed
Nov 1, 2021
Approved For Pub - Principal Register
Oct 28, 2021
Assigned To Examiner
Jul 6, 2021
New Application Office Supplied Data Entered
Apr 2, 2021
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
